YKL-06-062 is primarily used in scientific research as a selective inhibitor of soluble epoxide hydrolase (sEH), an enzyme involved in the metabolism of bioactive lipid mediators. By inhibiting sEH, this compound helps stabilize endogenous epoxy-fatty acids, such as epoxyeicosatrienoic acids (EETs), which have anti-inflammatory, analgesic, and vasodilatory properties. It is commonly employed in studies related to inflammatory pain, neuropathic pain, and neuroinflammation, particularly in models of multiple sclerosis and other central nervous system disorders. Its ability to cross the blood-brain barrier makes it especially valuable for investigating neuroprotective strategies and modulating central inflammatory pathways. Researchers also explore its potential in cardiovascular and metabolic disease models due to the role of EETs in regulating blood pressure and insulin sensitivity.